Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.

Arthritis research & therapy - 7 Mar 2017

Ajeganova Sofia, Tesfa Daniel, Hägglund Hans, Fadeel Bengt, Vedin Inger, Zignego Anna Linda, Palmblad Jan

Abstract excerpt

BACKGROUND: The causes and mechanisms of late-onset neutropenia (LON) following rituximab treatment in patients with rheumatic diseases are not known. In this study, we aimed to investigate the role of established Fcγ receptor gene (FCGR) polymorphisms and B-cell-activating factor (BAFF) gene promoter polymorphisms for the development of LON and for the efficacy of rituximab in patients with rheumatic diseases....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Neutropenia

Share to Receptors, IgG

Share to Rheumatic Diseases

Share to Rituximab

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28270182
DOI: 10.1186/s13075-017-1241-0
PMCID: PMC5341184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.PMID 28270182Read ↗

Rituximab‐induced late onset neutropenia in newly‐diagnosed B‐cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphismSemantic proximity Read ↗

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.Semantic proximity Read ↗

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritisSemantic proximity Read ↗

Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus.Semantic proximity Read ↗

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized MedicineSemantic proximity Read ↗

Fcgamma receptors: structure, function and role as genetic risk factors in SLE.Semantic proximity Read ↗

Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseases.Semantic proximity Read ↗

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.Semantic proximity Read ↗

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.Semantic proximity Read ↗

Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cellsSemantic proximity Read ↗

High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia.Semantic proximity Read ↗

Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.